The in vitro activity of BMY-28142, a new cephalosporin, was tested by a broth microdilution system and compared with those of cefotaxime, ceftazidime, cefoperazone, moxalactam, and HR 810 against 747 bacterial isolates, one-third of which were resistant to one or more third-generation cephalosporins. BMY-28142 was the most active drug tested against 326 Enterobacteriaceae with an MIC for 90% of the organisms tested (MIC90) of 1.0 ,Ig/ml. Against these Enterobacteriaceae the relative activities were: BMY-28142 > HR 810 > moxalactam and ceftazidime > cefotaxime > cefoperazone. For cefotaxime-and cefoperazone-resistant strains, the MIC90 of BMY-28142 was 4.0 ,ug/ml (compared with 0.13 ,ug/ml for susceptible strains 577, 1983).
BMY-28142 is a new parenteral cephalosporin with the structure 7-[a-(2-aminothiozol-4-yl)-a-(7)-methoximinoacetamido] -3 -(1 -methylpyrrolidinio) -methyl -3 -cephem-4-carboxylate. In preliminary studies it has demonstrated excellent activity against the Enterobacteriaceae, Pseudomonas aeruginosa, staphylococci, and streptococcal species other than enterococci (6; M. Bies, R. E. Buck, T. A. Pursiano, D. R. Chisholm, Y. H. Tsai, M. Misiek, K. E. Price, and F. Leitner, Program Abstr. 23rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 577, 1983) .
In this study, we compared the in vitro activity of BMY-28142 in a broth microdilution system with those of four third-generation cephalosporins: cefotaxime, ceftazidime, cefoperazone, and moxalactam, as well as with HR 810, a structurally similar and potent new cephalosporin (4) . The ,-lactamase stability of BMY-28142 and ,-lactamase inhibition by this drug are also reported. Susceptibility testing. For most organisms, MICs were determined by broth microdilution methods as described by the National Committee for Clinical Laboratory Standards (7) and in previous studies (2) (3) (4) . For testing nonenterococcal streptococci and Neisseria gonorrhoeae, an agar dilution method was used, which has been described previously in more detail (1) . A sample of 106 nonfastidious organisms were also tested simultaneously by both agar dilution and broth microdilution methods to assess the comparability of the results of the two methods (7) . The drug concentrations tested were serial twofold increments ranging from 0.008 to 256 ,ug/ml for BMY-28142 and HR 810 and from 0.06 to 32 ,ug/ml for cefotaxime, cefoperazone, moxalactam, and ceftazidime. The lowest concentration inhibiting the growth of an inoculum containing about 5 x 105 CFU/ml after 16 to 20 h of aerobic incubation at 35°C was considered the MIC in broth microdilution tests. For agar dilution, the inoculum contained about 104 CFU per spot. (6) , Morganella morganii (8), Salmonella enteritidis (9), Serratia liquefaciens (2), and Shigella spp. (9) .
MATERIALS AND METHODS
Includes P. acidovorans (3), P. cepacia (4), P. maltophilia (4), P. putida (5), and P. stutzeri (9) . d Not tested. types I to V (9) . One commercially prepared (BBL Microbiology Systems, Cockeysville, Md.) ,-lactamase derived from Bacillus cereus was also studied. The reaction mixtures 'were monitored for 20 min on a scanning UV spectrophotometer (model 552; The Perkin-Elmer Corp., Norwalk, Conn.) at wavelengths of 258 to 482 nm. Nitrocefin and cefaloridin served as the reference labile P-lactam, and the hydrolysis rate of the test 3-lactam relative to that of nitrocefin was the relative hydrolysis rate. In the 1B-lactamase inhibition studies, 0.1, 1.0, 10, 100, or 1,000 ,umol of BMY-28142 (or other 3-lactam) was added to the nitrocefin-p-lactamase reaction mixture, and the hydrolysis rates were calculated as above. The inhibition studies were also confirmed by a previously described method based on a When the gram-negative organisms were divided into resistant and susceptible categories based on resistance (MIC -16 ,ug/ml) to one or more of the third-generation drugs (cefotaxime, cefoperazone, and moxalactam) versus susceptibility to all three drugs, the MIC differences between BMY-28142 and the third-generation drugs was most apparent with the Enterobacteriaceae (Table 2 ). The differences among the resistant population were twice those of the susceptible population for cefoperazone and cefotaxime. Among the staphylococci, the differences in MIC betweenBMY-28142 and the other test drugs were not influenced appreciably by P-lactamase production ( Table 2 ).
Of 106 isolates tested with BMY-28142 by both agar dilution and broth microdilution methods, 58% had identical results by the two methods, and all but three (97.2%) had the same (±1) dilution endpoints. Three isolates yielded results showing an improved spectrum of in vitro antimicrobial activity. Of the five comparison drugs studied, the activity and spectrum of BMY-28142 were most similar to those of HR 810, but some differences were noted. Generally, BMY-28142 was slightly more active than HR 810 against gram-negative bacteria and less active against gram-positive bacteria. It was the most active agent tested against Enterobacteriaceae and second only to ceftazidime against pseudomonads. It was comparable to cefotaxime against staphylococci and nonenterococcal streptococci, but it was the least active of the drugs that could be compared against the enterococci. Furthermore, this excellent activity against gram-negative bacteria was observed against a collection of bacteria (particularly Enterobacteriaceae) resistant to thirdgeneration cephalosporins (Table 2 ). Of note are the greater MIC differences between BMY-28142 and some third-generation cephalosporins (particularly cefoperazone and cefotaxime) with resistant strains of Enterobacteriaceae compared with susceptible strains.
The excellent spectrum of BMY-28142, its virtual complete resistance to the action of common ,3-lactamases, and its low affinity for these enzymes are characteristics that make this a promising drug. Studies on its toxicology and pharmacokinetics in humans are required to further analyze the significance of these in vitro data.
